MannKind stock hits 52-week low at $3.70

MannKind (NASDAQ:MNKD) Corporation’s stock has reached a new 52-week low, hitting $3.70. This marks a significant downturn for the biopharmaceutical company, which has seen its stock price decline by 20.29% over the past year. Despite the recent decline, InvestingPro data shows the company maintains strong fundamentals with 32.5% revenue growth and a favorable PEG ratio of 0.16, suggesting potential value at current levels. The drop to this new low highlights ongoing challenges for MannKind, as it navigates a competitive and evolving industry landscape. Investors and analysts will be closely watching for any strategic adjustments or market developments that could influence the company’s future performance and stock valuation. InvestingPro analysis reveals eight additional key insights about MannKind’s financial health and valuation metrics, available in the comprehensive Pro Research Report, which provides deep-dive analysis of 1,400+ top US stocks.

In other recent news, MannKind Corporation reported its first-quarter 2025 financial results, revealing revenue that exceeded expectations at $78.35 million, marking an 18% year-over-year increase. However, the company’s earnings per share (EPS) slightly missed forecasts, coming in at $0.04 compared to the anticipated $0.042. The revenue growth was driven by a 32% increase in Tyvaso DPI royalties and an 18% rise in collaboration and services revenue. MannKind also announced the departure of its Chief Medical (TASE:BLWV) Officer, Burkhard Blank, with a transition plan set for him to remain as a non-executive employee until August 1, 2025. Additionally, MannKind is preparing to present findings from its INHALE-1 clinical trial at the American Diabetes Association’s Scientific Sessions, focusing on its inhaled insulin powder, Afrezza, for pediatric use. The company plans to submit a Supplemental Biologics License Application for a pediatric indication of Afrezza by mid-year. These developments reflect MannKind’s ongoing efforts to expand its market presence and product offerings.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.